Drugs / MUC1 peptide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT00986609 | Aug 2009 → Aug 2013 | inflammatory breast carcinoma, triple-negative breast carcinoma | Joseph Baar, MD, PhD | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUC-1 peptide | “MUC1 peptide-poly-ICLC adjuvant vaccine” NCT00986609 ↗1“MUC-1 peptide vaccine” NCT00986609 ↗ |
| Modality | Vaccine | “MUC1 peptide-poly-ICLC adjuvant vaccine” NCT00986609 ↗ |
| Route | Subcutaneous | “MUC-1 peptide vaccine subcutaneously” NCT00986609 ↗ |